Related Experiment Video
Updated: May 23, 2026

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
Published on: July 16, 2012
Resistance to anti-HCV protease inhibitors
Alexander J Thompson1, Stephen A Locarnini, Michael R Beard
1St Vincent's Hospital (Melbourne), Fitzroy, Victoria, Australia. alexander.thompson@svhm.org.au
Abstract:
The era of direct acting antiviral therapy for HCV infection has dawned with the recent approval of the NS3 protease inhibitors telaprevir and boceprevir. The development of DAA therapy is an exciting advance for clinicians and patients, but it will also bring new challenges. For the first time, drug resistance has become an issue to consider in the management of HCV. This brief review summarizes the current literature concerning resistance to the HCV NS3 protease inhibitors, both experimental and clinical, and identifies the key questions facing the field.
Related Concept Videos
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Retrovirus Life Cycles
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Inhibitors of Viral Protein Synthesis
Hepatic Drug Excretion: Influencing Factors

